Morgan Stanley lowered the firm’s price target on Moderna to $70 from $94 and keeps an Equal Weight rating on the shares. The firm is updating its model to reflect the company’s pipeline prioritization and updated financial guidance at its R&D Day that warned on the potentially lower vaccination rates and competitive pressures, the analyst tells investors in a research note. In the COVID/flu franchise, Morgan Stanley lowers its sales in 2026, where risk-adjusted peak sales goes to $3.1B from $5.0B, the firm stated.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- ‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
- Boeing factory workers strike halts 737 MAX production: Morning Buzz
- Moderna, Halliburton downgraded: Wall Street’s top analyst calls
- Moderna price target lowered to $75 from $90 at RBC Capital